Urological Oncology: Adrenal, Renal, Ureteral and Retroperitoneal Tumors | Journal of Urology

” Re: Evaluation of Axitinib to Downstage cT2a Renal Tumours and Allow Partial Nephrectomy: A Phase II Study .” The Journal of Urology, 203(1), pp. 28–29 © 2020 by American Urological Association Education and Research, Inc.

Read the full article here

Related Articles